<p>Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to scale up.</p><p>⭐️ ABOUT THE SPEAKER</p><p>Claus first joined Novozymes in 1993 and led its R&amp;D both in Denmark and the US, with six years as CSO. He has a Master’s degree in biochemistry and an MBA.</p><p>🔗 LINKS MENTIONED</p><ul><li>Novonesis’ website — <a href="https://www.novonesis.com/en" target="_blank" rel="ugc noopener noreferrer">https://www.novonesis.com/en</a></li><li>Merger of Novozymes and Chr Hansen — <a href="https://www.novonesis.com/en/news/novozymes-and-chr-hansen-announce-name-future-combined-company-novonesis" target="_blank" rel="ugc noopener noreferrer">https://www.novonesis.com/en/news/novozymes-and-chr-hansen-announce-name-future-combined-company-novonesis</a></li><li>Novonesis’ nine-month results in 2025 — <a href="https://backend.novonesis.com/sites/default/files/document/2025-11/2025_46_9M_Interim_report.pdf" target="_blank" rel="ugc noopener noreferrer">https://backend.novonesis.com/sites/default/files/document/2025-11/2025_46_9M_Interim_report.pdf</a></li><li>Novonesis and Benchling partnership in 2024 — <a href="https://www.benchling.com/news/novonesis-and-benchling-long-term-partnership-to-power-rd" target="_blank" rel="ugc noopener noreferrer">https://www.benchling.com/news/novonesis-and-benchling-long-term-partnership-to-power-rd</a></li><li>EU biosolutions — <a href="https://research-and-innovation.ec.europa.eu/research-area/environment/bioeconomy/bio-based-products-and-processes_en" target="_blank" rel="ugc noopener noreferrer">https://research-and-innovation.ec.europa.eu/research-area/environment/bioeconomy/bio-based-products-and-processes_en</a></li></ul><p><br /></p><p><br /></p><p>📜 TRANSCRIPT</p><p><br /></p><p>Read the full transcript here: <a href="https://flot.bio/episode/claus-crone-fuglsang-novonesis-biosolutions/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/claus-crone-fuglsang-novonesis-biosolutions/</a></p><p>💸 DONATE</p><p>We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: <a href="https://www.paypal.me/PhilipHemme" target="_blank" rel="ugc noopener noreferrer">https://www.paypal.me/PhilipHemme</a></p><p>⭐️ SPONSORSHIP</p><p><br /></p><p>Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!</p><p>🫶 FOLLOW US</p><ul><li>Newsletter: <a href="http://eepurl.com/h_fnmH" target="_blank" rel="ugc noopener noreferrer">http://eepurl.com/h_fnmH</a></li><li>LinkedIn: <a href="https://www.linkedin.com/company/flot-bio/" target="_blank" rel="ugc noopener noreferrer">https://www.linkedin.com/company/flot-bio/</a></li><li>X (Twitter): <a href="https://x.com/FlotBio" target="_blank" rel="ugc noopener noreferrer">https://x.com/FlotBio</a></li></ul><p>🙏 LIKE/FOLLOW/REVIEW</p><p><br /></p><p>Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.</p><p>🎙️ABOUT FLOT.BIO</p><p><br /></p><p>Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.</p><p>⏰ TIMESTAMPS</p><ul><li>[00:00:00] Intro</li><li>[00:02:19] Novonesis: the Novozymes and Chr Hansen merger</li><li>[00:09:51] Under the consumer radar</li><li>[00:12:52] Business divisions and myriad applications</li><li>[00:20:46] The scaling challenge in biosolutions</li><li>[00:27:39] Novonesis’ profitability and growth</li><li>[00:36:34] Genetic engineering and cool patents</li><li>[00:47:57] Novonesis’ growing AI use</li><li>[00:56:34] Claus Crone Fuglsang’s enthusiasm for his work</li><li>[01:00:09] Industrial biotech globally</li><li>[01:04:15] Quick-fire questions</li></ul>